Physician profile
Mansour Isckarus
NPI 1770581787
$3,023.84
in general payments reported to CMS, 2019-2025
31 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.14 · 2021: $28.87 · 2022: $289 · 2023: $942 · 2024: $740 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659 · Education: $30.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.63 |
| Education | $30.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $466.12 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.50 | 2020-2025 | Opdivo, Opdualag |
| Pfizer INC. | $225.96 | 2022-2025 | |
| Janssen Biotech, INC. | $206.96 | 2024-2025 | Erleada, Akeega, Rybrevant |
| Eisai INC. | $204.22 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.94 | 2023-2025 | Calquence, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $142.88 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $138.23 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $136.43 | 2022-2025 | Keytruda |
| Array Biopharma INC | $119.48 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Astellas Pharma US INC | $105.20 | 2023-2025 | Xtandi, Padcev |
| Abbvie INC. | $96.09 | 2024-2025 | |
| Genentech USA, INC. | $77.48 | 2021-2024 | Venclexta, Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $67.84 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Amgen INC. | $61.04 | 2023 | Lumakras |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $59.62 | 2023 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $54.36 | 2023-2025 | Enhertu |
| Gilead Sciences, INC. | $54.05 | 2022-2024 | |
| Taiho Oncology, INC. | $50.72 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $47.89 | 2022-2025 | Libtayo |
| Foundation Medicine, INC. | $43.35 | 2023 | |
| Novocure INC. | $30.04 | 2025 | Optune Lua (Novottf-200t) |
| Kite Pharma, INC. | $27.18 | 2023 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $23.47 | 2024 | Somatuline Depot, Onivyde |
| Lilly USA, LLC | $21.20 | 2022 | |
| Seagen INC. | $18.69 | 2023 | Adcetris |
| Incyte Corporation | $18.39 | 2025 | Monjuvi, Zynyz |
| Aveo Pharmaceuticals, INC. | $17.83 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $16.59 | 2023 | Epkinly |
| Genzyme Corporation | $15.68 | 2021 | |
| Adc Therapeutics America, INC. | $15.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansour Isckarus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.